MX2019012929A - Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4). - Google Patents

Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4).

Info

Publication number
MX2019012929A
MX2019012929A MX2019012929A MX2019012929A MX2019012929A MX 2019012929 A MX2019012929 A MX 2019012929A MX 2019012929 A MX2019012929 A MX 2019012929A MX 2019012929 A MX2019012929 A MX 2019012929A MX 2019012929 A MX2019012929 A MX 2019012929A
Authority
MX
Mexico
Prior art keywords
useful
thienopyridines
benzothiophenes
compounds
irak4 inhibitors
Prior art date
Application number
MX2019012929A
Other languages
English (en)
Inventor
Li Ling
Ahmad Saleem
Hynes John
A Negash Lidet
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2019012929A publication Critical patent/MX2019012929A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen los compuestos de la Fórmula (I) o una sal o un profármaco del mismo, en donde: X es CR4 o N; Y es CR5 o N; siempre que solo uno de X e Y sea N; (R1) es: o; en donde R1, R1a, R1b, R1c, R2 y R3 se definen en la presente. También se describen métodos para usar tales compuestos como moduladores de IRAK4, y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles para tratar, prevenir o ralentizar enfermedades inflamatorias y autoinmunitarias, o para el tratamiento contra el cáncer.
MX2019012929A 2017-05-11 2018-05-10 Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4). MX2019012929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762504956P 2017-05-11 2017-05-11
PCT/US2018/031945 WO2018209012A1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors

Publications (1)

Publication Number Publication Date
MX2019012929A true MX2019012929A (es) 2020-01-14

Family

ID=62245511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012929A MX2019012929A (es) 2017-05-11 2018-05-10 Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4).

Country Status (27)

Country Link
US (1) US10829496B2 (es)
EP (1) EP3621960B1 (es)
JP (1) JP7154229B2 (es)
KR (1) KR102604900B1 (es)
CN (1) CN110612298B (es)
AR (1) AR111689A1 (es)
AU (1) AU2018265130B2 (es)
BR (1) BR112019023290A2 (es)
CA (1) CA3062602A1 (es)
CL (1) CL2019003198A1 (es)
CO (1) CO2019012494A2 (es)
CY (1) CY1124552T1 (es)
DK (1) DK3621960T3 (es)
EA (1) EA039189B1 (es)
ES (1) ES2889926T3 (es)
HR (1) HRP20211583T1 (es)
HU (1) HUE056493T2 (es)
IL (1) IL270494B (es)
LT (1) LT3621960T (es)
MX (1) MX2019012929A (es)
PE (1) PE20191817A1 (es)
PL (1) PL3621960T3 (es)
PT (1) PT3621960T (es)
RS (1) RS62430B1 (es)
SI (1) SI3621960T1 (es)
TW (1) TW201900640A (es)
WO (1) WO2018209012A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7366031B2 (ja) 2017-09-22 2023-10-20 カイメラ セラピューティクス， インコーポレイテッド タンパク質分解剤およびそれらの使用
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
JP2021508703A (ja) 2017-12-26 2021-03-11 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
KR20210111252A (ko) 2018-11-30 2021-09-10 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
EP4004000A1 (en) * 2019-07-23 2022-06-01 Bristol-Myers Squibb Company Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
TW202136251A (zh) 2019-12-17 2021-10-01 美商凱麥拉醫療公司 Irak降解劑及其用途
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
CN111285844B (zh) * 2020-02-24 2022-08-12 河南师范大学 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
JP4541695B2 (ja) 2001-06-15 2010-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとしての５−（２−アミノピリミジン−４−イル）ベンズイソキサゾール
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
DE602004021558D1 (de) 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
EP1651636A1 (en) 2003-07-10 2006-05-03 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
JP2008533019A (ja) 2005-03-09 2008-08-21 シェーリング コーポレイション Ｋｓｐキネシン活性を阻害するための化合物
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2636242A1 (en) 2006-01-30 2008-05-29 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
CA2685588A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Sa Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JP5254693B2 (ja) 2008-07-30 2013-08-07 三菱重工業株式会社 Ｎｉ基合金用溶接材料
WO2010058846A1 (ja) 2008-11-21 2010-05-27 アステラス製薬株式会社 ４，６-ジアミノニコチンアミド化合物
CN102227409B (zh) 2008-11-28 2014-03-26 兴和株式会社 吡啶-3-甲酰胺衍生物
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
MX2012002591A (es) 2009-09-03 2012-04-02 Allergan Inc Compuestos como moduladores de tirosina cinasas.
BR112012010220A2 (pt) 2009-10-30 2021-02-23 Janssen Pharmaceutical N.V. piridinas fenóxi-substituídas como modulares do receptor opioide
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
RU2013148405A (ru) 2011-04-29 2015-06-10 Айкан Скул Оф Медисин Эт Маунт Синай Ингибиторы киназ
CN104159896B (zh) 2012-01-13 2017-05-24 百时美施贵宝公司 用作激酶抑制剂的杂环取代的吡啶基化合物
ES2630705T3 (es) 2012-01-13 2017-08-23 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas
JP6096219B2 (ja) 2012-01-13 2017-03-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物
WO2014074675A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
JP6215338B2 (ja) 2012-11-08 2017-10-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
MA39838B1 (fr) 2014-04-04 2019-05-31 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
WO2016144844A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Carboxamide inhibitors of irak4 activity
WO2016144849A1 (en) * 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of irak4 activity
JP6720225B2 (ja) 2015-06-24 2020-07-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリール置換のアミノピリジン化合物
CN107849039B (zh) 2015-06-24 2020-07-03 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
MX2018002402A (es) 2015-08-27 2018-04-11 Pfizer Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).

Also Published As

Publication number Publication date
CY1124552T1 (el) 2022-07-22
CL2019003198A1 (es) 2020-03-20
KR20200004871A (ko) 2020-01-14
AU2018265130B2 (en) 2022-03-24
KR102604900B1 (ko) 2023-11-21
PT3621960T (pt) 2021-09-16
HRP20211583T1 (hr) 2022-01-07
PE20191817A1 (es) 2019-12-27
EP3621960B1 (en) 2021-08-04
EP3621960A1 (en) 2020-03-18
WO2018209012A1 (en) 2018-11-15
HUE056493T2 (hu) 2022-02-28
PL3621960T3 (pl) 2021-11-08
JP2020519596A (ja) 2020-07-02
CN110612298B (zh) 2023-05-05
EA039189B1 (ru) 2021-12-15
EA201992674A1 (ru) 2020-04-06
CO2019012494A2 (es) 2020-01-17
AR111689A1 (es) 2019-08-07
IL270494B (en) 2022-04-01
BR112019023290A2 (pt) 2020-06-16
US10829496B2 (en) 2020-11-10
LT3621960T (lt) 2021-10-11
SI3621960T1 (sl) 2021-11-30
RS62430B1 (sr) 2021-11-30
CA3062602A1 (en) 2018-11-15
CN110612298A (zh) 2019-12-24
AU2018265130A1 (en) 2020-01-02
ES2889926T3 (es) 2022-01-14
TW201900640A (zh) 2019-01-01
DK3621960T3 (da) 2021-09-27
US20200062777A1 (en) 2020-02-27
JP7154229B2 (ja) 2022-10-17

Similar Documents

Publication Publication Date Title
MX2019012929A (es) Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4).
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
PH12017502195A1 (en) Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MX2015016085A (es) Derivados de heterociclicos.
MX2018004664A (es) Antagonistas de ep4.
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2017011434A (es) Compuestos heterociclicos triciclicos sustituidos.
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
PH12017501879A1 (en) Methods for treating cancer
MX2017011433A (es) Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf).
MX2017011577A (es) Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
AU2019257509A1 (en) Androgen receptor modulators and methods for their use